Health ❯ Healthcare ❯ Biotechnology

Gene Therapy

Duchenne Muscular Dystrophy Huntington's Disease Clinical Trials Safety Concerns FDA Cholesterol Management Sarepta Therapeutics Cardiovascular Disease Patient Safety Elevidys Hemophilia A Kriya Therapeutics Chronic Diseases Dystrophic Epidermolysis Bullosa CAR-T Therapy RNA Interference Ophthalmology Genetic Agency AAV-SLB101 Adeno-Associated Virus (AAV) Bluebird Bio Market Trends

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

The agreement deepens Lilly’s push into ophthalmic gene medicines following its October move to buy Adverum Biotechnologies.

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership

Regulators Halt Elevidys Gene Therapy Worldwide After Safety Failures

Sarepta Defies FDA, Keeps Duchenne Gene Therapy on the Market

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure